Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial.
Shuta Ishigami, Shinichi Ohtsuki, Suguru Tarui...
https://pubmed.ncbi.nlm.nih.gov/25403163/Actively Recruiting
Led by Metcela Inc. · Updated on 2026-10-19
40
Participants Needed
4
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and effectiveness of an intracoronary injection of autologous cardiac stem cells called JRM-001 in children with a functional single ventricle, a serious heart condition, after reconstructive surgery. This trial focuses on pediatric patients scheduled for stage 2 Glenn or stage 3 Fontan surgeries who have heart failure and reduced heart function. Participants in this study will be randomly assigned to receive either a single dose of JRM-001 stem cells at 3x105 cells per kilogram of body weight or to continue with usual care without additional intervention. This is a single-blind, parallel-group study conducted by Metcela Inc. The study will follow patients for up to 12 months after treatment to monitor changes in heart function and overall health. During the study, participants will undergo assessments including MRI, echocardiograms, and cardiac catheterization at various time points to measure heart function changes such as ejection fraction and ventricular stiffness. Researchers will also evaluate heart failure symptoms, quality of life, and track any adverse events. The total study duration allows observation from baseline up to 12 months post-treatment to understand the treatments impact and safety.
CONDITIONS
Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)
M
Metcela Inc. (former Japan Regenerative Medicine Co., Ltd.)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Metcela Inc.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Duration - Single treatment at surgery time
Participants receive a single intracoronary injection of autologous cardiac stem cells (JRM-001) or continue with usual care after reconstructive surgery.
1 treatment visit
Duration - 12 months
Participants undergo heart function assessments by MRI, echocardiograms, and cardiac catheterization at baseline and at 3, 6, and 12 months to monitor changes and safety.
Multiple visits at baseline, 3, 6, and 12 months
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Shuta Ishigami, Shinichi Ohtsuki, Suguru Tarui...
https://pubmed.ncbi.nlm.nih.gov/25403163/Shuta Ishigami, Shinichi Ohtsuki, Takahiro Eitoku...
https://pubmed.ncbi.nlm.nih.gov/28052915/Suguru Tarui, Shuta Ishigami, Daiki Ousaka...
https://pubmed.ncbi.nlm.nih.gov/26232942/Metcela Inc.
Lead Sponsor